spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  perifosine 

 HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2010
AEterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Dec 2009
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 20 May 2009
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2009
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2008
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Mar 2008
Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2007
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
perifosine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.